Suppr超能文献

“糖胖病”的治疗:超越药物治疗。

Treatment of 'Diabesity': Beyond Pharmacotherapy.

机构信息

Stem Cell Research/Biochemistry, National Institute of Nutrition, Hyderabad-500007, India.

出版信息

Curr Drug Targets. 2018;19(14):1672-1682. doi: 10.2174/1389450119666180621093833.

Abstract

Obesity is a prominent risk factor for type 2 diabetes. Management of type 2 diabetes requires weight management in addition to glycemic parameters. For obese type 2 diabetes patients, metformin, Sodium-glucose co-transporter-2 inhibitors or Glucagon-Like Peptide-1 Receptor Agonists should be prescribed as the first priority for controlling both hyperglycemia and body weight or fat distribution. The combination of these drugs with sulfonylureas, thiazolidinediones, and insulin may also be required in chronic cases. These drugs cause weight gain. Fortunately, many phytochemicals having a beneficial effect on diabetes and obesity, have minimum side-effects as compared to synthetic drugs. This review discusses the treatment strategies for controlling glycemia and weight management, with the focus on anti-diabetic drugs and phytochemicals. Glucagonostatic role, activation of Adenosine monophosphate-activated protein kinase and adipocyte targeting potential of anti-diabetic drugs and phytochemicals are also discussed.

摘要

肥胖是 2 型糖尿病的一个显著危险因素。2 型糖尿病的管理除了血糖参数外,还需要体重管理。对于肥胖的 2 型糖尿病患者,应将二甲双胍、钠-葡萄糖共转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂作为控制高血糖和体重或脂肪分布的首要药物。在慢性病例中,这些药物可能还需要与磺酰脲类、噻唑烷二酮类和胰岛素联合使用。这些药物会导致体重增加。幸运的是,与合成药物相比,许多对糖尿病和肥胖有有益影响且副作用最小的植物化学物质。本综述讨论了控制血糖和体重管理的治疗策略,重点是抗糖尿病药物和植物化学物质。还讨论了抗糖尿病药物和植物化学物质的降血糖作用、激活腺苷单磷酸激活蛋白激酶和靶向脂肪细胞的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验